ESR1 and its antagonist fulvestrant in pituitary adenomas
ESR1 and its antagonist fulvestrant in pituitary adenomas
复制标题
ESR1及其拮抗剂氟维司群在垂体腺瘤中的作用
DOI：
10.1016/j.mce.2016.12.029
复制
发表时间：
2017-03-05
影响因子：
4.1
通讯作者：
Zhang, Yazhuo
中科院分区：
文献类型：
--
作者：
Gao, Hua;Xue, Yake;Zhang, Yazhuo
雌激素在垂体腺瘤（PA）的发病机制中发挥着关键作用。该研究旨在评估 289 例 PA 病例中的雌激素受体 α (ESR1) 水平、其与临床病理特征的关联以及作为癌症治疗的目标。在本研究中，通过组织微阵列（TMA）评估ESR1水平。氟维司群的作用是通过在F344大鼠中皮下注射17β-雌二醇建立的催乳素瘤动物模型来确定的。评估不同组的垂体体积和重量。在垂体腺瘤细胞系 GH3 和 JT1-1 中探讨氟维司群对细胞增殖和细胞侵袭的影响。 191/289例ESR1阳性细胞率均大于50%。 ESR1高水平病例（年龄≥50岁）为103/133，ESR1高水平病例（年龄≥50岁）为88/156。
Estrogen has a key role in the pathogenesis of pituitary adenomas (PAs). The study was to evaluate the estrogen receptor alpha (ESR1) level in 289 PAs cases, its association with clinicopathologic features and serving as a target of cancer treatment. In this study, the ESR1 level was evaluated by tissue microarray (TMA). The effect of fulvestrant was determined by an animal model of prolactinoma established by subcutaneous injection of 17 beta-estradiol in F344 rats. The volume and weight of the pituitary were assessed in the different groups. The effects of fulvestrant on cell proliferation and cell invasion were explored in the pituitary adenoma cell lines GH3 and JT1-1. The ESR1-positive cells rates of 191/289 cases were more than 50%. And ESR1 high level cases (age >= 50) were 103/133, and 88/156 in cases (age